Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unemployment is high in this population, and even among those employed, individuals are often working below their skills and abilities 220,221 .”
From Autism spectrum disorder (2020) · cites this paper as [221]
In the citing paper
“However, several drug development programs based on the inhibition of mGluR signaling for the treatment of FXS (Novartis and Seaside Therapeutics) were recently closed because efficacy studies in adolescents and adults showed no measurable benefits 114,115 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [114]
In the citing paper
“Exploratory biomarkers and endophenotypes tested in a substudy (n = 56) of the mavoglurant trials suggests an improvement relative to placebo in gaze towards the eye region on an eye-tracking task and in performance on a computerized executive function battery69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Mild side effects (headaches, dizziness, insomnia and vomiting) were observed in about 20% of FXS patients with mavoglurant at higher dose levels69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Conversely, the larger studies of mavoglurant, basimglurant and arbaclofen included over 100 participants and were able to provide conclusions across secondary outcome measures69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Kaufer, D., Cummings, J. L., Ketchel, P., Smith, V. M., MacMillan, A., Shelley, T., López, O. L., & DeKosky, S. T. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.2.233 · Cited by 1,973
Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025014929212 · Cited by 1,611
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
(1985) · PubMed · Cited by 1,427
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Reliability and validity of a computerized neurocognitive test battery, CNS vital signs
GUALTIERI, C., & JOHNSON, L. (2006) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2006.05.007 · Cited by 873 · cited 1×
“CNS VS TheCNSVS is a computerized testing battery focused onworkingmemory; the following four modules were used: Visual Memory Test (VIM), Symbol-Digit Coding (SDC), Perception of Emotions Test (POET), and three-part Continuous Performance Test (CPT) [WorkingMemory Test (WMT)] (31).”
MethodLam, K. S. L., & Aman, M. G. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0213-z · Cited by 793
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.-P., & Mandel, J.-L. (1993) · Nature Genetics · doi:10.1038/ng0893-335 · Cited by 780 · cited 1×
“This mutation is associated with complete or partial methylation at the FMR1 promoter, resulting in the loss or significant reduction of expression of the gene product FMRP (fragile X mental retardation protein) (7).”
Background
Research works printed but not linked: 2
- W. Guy in ECDEU Assessment Manual for Psychopharmacology (National Institute of Mental Health Psychopharmacology Research Branch Mental Health Administration Rockville MD 1976) pp. 217–222.
- 10.1176/jnp.12.2.233 · DOI · Paper page
Cited by
Items 201–282 of 282
Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
Scharf, S. H., Gasparini, F., Spooren, W. P. J. M., & Lindemann, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00018-4 · Cited by 3
Stanfield, A. C., & McKechanie, A. G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2510408 · Cited by 3
“…there is significant optimism around future targeted treatments, this is tempered by the repeated negative findings reported for another class of medication not discussed in the current review, the mGluR5 antagonists [102–105], despite very strong laboratory evidence of their potential efficacy.”
Disruptions in chloride transporter activity in autism spectrum disorders
Ferrari, D. C., & Ben‐Ari, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815318-5.00020-0 · Cited by 4
Kelleher, B., Protho, T., Hamrick, L. R., Smith, D., McCormick, C. E. B., DeMaria, A. L., Rispoli, M. J., & Seidl, A. H. (2022) · International review of research in developmental disabilities · doi:10.1016/bs.irrdd.2022.05.002 · Cited by 4
Arpone, M., Bretherton, L., Amor, D. J., Hearps, S. J. C., Rogers, C., Field, M. J., Hunter, M. F., Maria, L. S., Alliende, A. M., Slee, J., et al. (2022) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2022.104338 · Cited by 3
Molecular mechanisms for targeted treatments in fragile X syndrome
Miranda, I., & Hagerman, R. J. (2023) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2023.21 · Cited by 3
Self-citationChildress, E. S., Capstick, R. A., Crocker, K. E., Ledyard, M. L., Bender, A. M., Maurer, M. A., Billard, N. B., Cho, H. P., Rodriguez, A. L., Niswender, C. M., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00481 · Cited by 3
David, T. K., Prashanth, N. K., Rajendraswami, M., Pallalu, D., Castelhano, A. L., Kates, M. J., Blobaum, A. L., Jones, C. K., Emmitte, K. A., Conn, P. J., et al. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.07.100 · Cited by 3
mTOR signaling in proteostasis and its relevance to autism spectrum disorders
Faus-Garriga, J., 1 Departament de Ciències Experimentals i de la Salut, U. P. F., Novoa, I., & Ozaita, A. (2017) · AIMS Biophysics · doi:10.3934/biophy.2017.1.63 · Cited by 3
“Among those, the mGlu5 receptor antagonist AFQ056 (mavoglurant) failed in phase II clinical trial [147], indicating the need for additional research on other potential therapeutic approaches.”
From bedside to bench and back: Translating ASD models
Drozd, H. P., Karathanasis, S. F., Molosh, A. I., Lukkes, J. L., Clapp, D. W., & Shekhar, A. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.10.003 · Cited by 4
Turning the tide on targeted treatments for neurodevelopmental disorders
Hagerman, R. J., & Tuchman, R. F. (2019) · Neurology · doi:10.1212/wnl.0000000000007301 · Cited by 4
Self-citationTabatadze, N., Koniashvili, O., Melikishvili, G., Bienvenu, T., Cuisset, L., Tassone, F., Protic, D. D., Naneishvili, N., Zarandia, M., Gverdtsiteli, S., et al. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1645386 · Cited by 2
“For example, metabotropic glutamate receptor 5 (mGluR5) antagonists, such as mavoglurant, failed to show significant improvements in behavioral symptoms compared to placebo (17).”
Self-citationWilson, M. A., Sumera, A., Berk, E., & Booker, S. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1640921 · Cited by 3
Steenbergen, A. V., Kaur, M., Rubanarayana, K., & Bolduc, F. V. (2026) · Neurology Genetics · doi:10.1212/nxg.0000000000200373 · Cited by 2
Berry‐Kravis, E. (2022) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-127.2.90 · Cited by 3
Self-citationFragile X clinical features and neurobiology
Leigh, M. J., & Hagerman, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814409-1.00015-x · Cited by 2
Self-citationDupont, A.-C., Arlicot, N., Vercouillie, J., Sérrière, S., Maïa, S., Bonnet‐Brilhault, F., & Ribeiro, M. J. (2023) · Pharmaceuticals · doi:10.3390/ph16081127 · Cited by 2
Drugs to Tune Up Glutamatergic Systems: Modulators of Glutamate Metabotropic Receptors
Sengmany, K., & Gregory, K. J. (2017) · Neuromethods · doi:10.1007/978-1-4939-7228-9_8 · Cited by 2
Reflections on Clinical Trials in Fragile X Syndrome
Jønch, A. E., & Jacquemont, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00020-2 · Cited by 2
Self-citationBudimirovic, D. B., & Protic, D. D. (2016) · Vojnosanitetski pregled · doi:10.2298/vsp161006315b · Cited by 3
Prevalence of fragile X syndrome among patients with mental retardation in the west of Iran
Peyman, H., Haghani, K., Noori-Zadeh, A., & Bakhtiyari, S. (2018) · Frontiers in Biology · doi:10.1007/s11515-018-1508-0 · Cited by 2
A multiple comparison procedure for dose‐finding trials with subpopulations
Thomas, M., Bornkamp, B., Posch, M., & König, F. (2019) · Biometrical Journal · doi:10.1002/bimj.201800111 · Cited by 1
“The mutation leads to complete or partial methylation (PM) of the FMR1 promoter, which causes a complete loss or a reduction in the expression of the associated FMRP (fragile X mental retardation protein; Berry-Kravis et al., 2016).”
BackgroundResultAutomated Real-Time Tracking System for Socially-Housed Physically Identical Mice
Wang, Y., Savonenko, A. V., & Etienne‐Cummings, R. (2021) · IEEE Biomedical Circuits and Systems Conference (BioCAS) · doi:10.1109/biocas49922.2021.9645011 · Cited by 2
Harris, J. C., & Coyle, J. T. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780199928118.003.0016 · Cited by 3
Fragile X Syndrome and Premutation‐Associated Disorders
Hagerman, R. J. (2010) · Wiley eBooks · doi:10.1002/9780470893159.ch27 · Cited by 3
Self-citationPerche, O., Lesne, F., Patat, A. A., Raab, S., Twyman, R. E., Ring, R. H., & Briault, S. (2021) · Research Square · doi:10.21203/rs.3.rs-389870/v1 · Cited by 2
Fang, M., Deibler, S. K., Krishnamurthy, P. M., Wang, F., Rodríguez, P. M., Banday, S., Virbasius, C.-M. A., Sena‐Esteves, M., Watts, J. K., & Green, M. R. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1348478 · Cited by 1
Protic, D. D., Stojković, M., & Budimirovic, D. B. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-60213 · Cited by 1
Henderson, S. H., Ringuette, A. E., Whomble, D. L., Capstick, R. A., Richardson, A. E., Maurer, M. A., Billard, N. B., Lei, X., Wilkinson, J. C., Kethanapalli, S. H., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00896 · Cited by 1
Dhungel, A., & Bora, R. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03116-0 · Cited by 1
Targeting the GABAB Receptor in Fragile X Syndrome and Autism Spectrum Disorders
Healy, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-46044-4_13 · Cited by 2
Bratt‐Leal, A. M., Zhang, A., Wang, Y., & Loring, J. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00025-3 · Cited by 1
McCarty, N. (2022) · The Transmitter · doi:10.53053/ktuf7187 · Cited by 1
A Double Jeopardy: Loss of FMRP Results in DSB and Down-regulated DNA Repair.
Chakraborty, A., Grageda, A., Kuznetsov, V. A., & Feng, W. (2022) · PubMed · Cited by 1
Biomedical Interventions for Autism Spectrum Disorder
Lim, J. J., & Anagnostou, E. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-20792-1_20 · Cited by 1
Induced Pluripotent Stem Cells
Bratt‐Leal, A. M., Zhang, A., Wang, Y., & Loring, J. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00011-4 · Cited by 1
Translation in fragile X: no home runs in the first at-bat
Veenstra-VanderWeele, J. M. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9204-y · Cited by 1
“The results of the larger study, a two-group trial of one dose versus placebo in adults and adolescents (n = 125), parallel the negative findings in trials of mGluR5 negative allosteric modulators in adults and adolescents [9].”
Role of ATRX Chromatin Remodelling Factor in α‐Thalassaemia X ‐Linked Mental Retardation
Young, K. G., & Picketts, D. J. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0026558
Lázaro, M. T. (2016) · eScholarship (California Digital Library)
An Introduction to the CNS Section of Volume 7: Recent Approvals and Advances in CNS Drug Discovery
Hall, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803200-8.02004-6
Molecular mechanisms involved in altered differentiation of neural progenitors in Fragile X Syndrome
Achuta, V. S. (2018) · Helda - University of Helsinki Institutional Repository
Identifying barriers to clinical trial participation with families affected by fragile X syndrome
Eley, S. E. A. (2017) · Edinburgh Research Archive (University of Edinburgh)
Epigenetic dysregulation in the fragile X-related disorders
Usdin, K., & Kumari, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813796-3.00012-2
Genetics of autism spectrum disorders
Gupta, A. R., Fernandez, T. V., & Hoffman, E. J. (2020) · doi:10.1093/med/9780198713005.003.0028
Proteau-Lemieux, M. (2020) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
"Primaverano" pictórico / teatral
Simón, A. (2010) · La Ratonera: Revista asturiana de teatro
Computer modeling of allosteric modulators at G protein-coupled receptors
Brandt, A. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819771-4.00007-5
Fragile X clinical features and neurobiology
Leigh, M. J., & Hagerman, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00022-2
Self-citationNovel Approaches for Treating Pediatric Psychiatric Disorders
Prasad, S., & Cook, E. H. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0067
Fragile X-associated disorders
Hagerman, R. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00037-x
Self-citation(2023) · The MIT Press eBooks · doi:10.7551/mitpress/15380.003.0024
Novel treatment in managing autism
Pramanik, S. D., Dey, Y. N., Kumar, D., Singh, M. R., & Singh, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00015-9
Fragile X clinical features and neurobiology
Leigh, M. J., & Hagerman, R. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00036-4
Self-citationTreatment of Neurodevelopmental Disorders
van Karnebeek, C., Berry‐Kravis, E., & Gropman, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00079-2
Self-citationAbbeduto, L., Berry‐Kravis, E., Sterling, A. M., Sherman, S., Edgin, J. O., McDuffie, A. S., Hoffmann, A., Hamilton, D., Nelson, M., Aschkenasy, J. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12023523
Self-citationShim, Y., Yang, D. H., Eun, B., & Byeon, J. H. (2025) · Annals of Child Neurology · doi:10.26815/acn.2025.01060
“For example, several phase 3 trials of metabotropic glutamate receptor 5 (mGluR5) antagonists in fragile X syndrome failed to reproduce promising pre-clinical results [32], reflecting both biological heterogeneity and methodological limitations.”
Fonteneau, M., Terrier, C., Bolot, F., Pantouli, F., Brugoux, A., Malhaire, F., Wagnon, I. M., Borràs‐Tudurí, R., Rossolillo, P., McCort‐Tranchepain, I., et al. (2026) · Pharmacological Research · doi:10.64898/2026.01.12.699042
Merikle, E. P., Tich, N., Sebree, T. B., Hagerman, R. J., O’Quinn, S., Nomikos, G. G., & Bzdek, K. G. (2026) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-026-01054-9
Self-citationDissecting the role of calcium signaling in Fragile X syndrome
Castagnola, S. (2019) · theses.fr (ABES) · doi:10.70675/3d35096bz79d0z46edz8a70zb783a8f60257
Felgerolle, C. (2019) · theses.fr (ABES) · doi:10.70675/fbd5cf69zed5az4a57zbfdez48e26a937a72
Pathophysiological consequences of a Fragile X missense mutation
Garcia, M. P. (2020) · theses.fr (ABES) · doi:10.70675/b8e86263z5926z4a83zbaf6z0f61bf2d15f9
BKCa channels as therapeutic targets in neurodevelopmental disorders : focus on acoustic dysfunction
Ferraguto, C. (2024) · theses.fr (ABES) · doi:10.70675/38217611z1b01z43f4zb4b0z72d28aca79c3
Pathophysiology of the FMRP-R138Q Fragile X Syndrome missense mutation in mice
Chato-Astrain, I. (2025) · theses.fr (ABES) · doi:10.70675/ce8d1ccfz4554z4c55z8782z624e392f72a1
Toupin, A. (2022) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Swarup, V., Deepika, D., Garg, D., & Srivastava, A. K. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70445
Şahin, B. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179270
Blarcamesine improves EEG biomarkers of cortical dysfunction in a mouse model of fragile X syndrome
Jonak, C. R., Assad, S. A., Binder, D. K., Tran, J., Missling, C. U., & Kaufmann, W. E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786406
Bridging language phenotypes, neural dynamics and gene regulation in autism
Vinurel, M., Wang, X., Kordon, D., Jochaut, D., Speranza, M., Boeckx, C. A., & Giraud, A. (2026) · Imaging Neuroscience · doi:10.1162/imag.a.1396
“However, despite this strong biological rationale, these targeted pharmacological approaches have yielded modest and highly variable clinical outcomes to date (Berry-Kravis et al., 2016; Curatolo et al., 2015; Sclabassi et al., 2025).”
ATF4 Modulates Group 1 mGluR-Dependent molecular signaling, hippocampal plasticity and behavior
Wang, S., Yook, Y., Lizarazo, S., Lee, K. Y., Bortle, K. V., Rhodes, J. S., Christian, C. A., & Tsai, N. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03919-3
Gurgone, A. (2020) · Institutional Research Information System University of Turin (University of Turin)
Giri, S., Singh, P., Verma, D., Yadav, E., Dutta, S., & Yadav, G. (2026) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-026-00343-3
Metadata
- Authors
- Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., Barth, G. M., Jaecklin, T., Apostol, G., & von Raison, F.
- Affiliations
- Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.
- National Reference Center for Fragile X and Other X-Linked Intellectual Disabilities, CIC 1407 INSERM, Hospices Civils de Lyon, Université de Lyon, 69002 Lyon, France.
- University of California Davis Medical Center (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- Emory University (US)
- Novartis (Germany) (DE)
- Novartis Pharmaceuticals SAS, 92500 Rueil-Malmaison, France.
- Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.
- Novartis (United States) (US)
- Universitätsklinikum Tübingen (DE)
- Novartis (Switzerland) (CH)
- Neuroscience Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-01-13
- Volume
- 8
- Issue
- 321
- Pages
- 321ra5-321ra5
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2237631658
- Cited by
- 270
- References
- 35
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 23 · 2021: 21 · 2020: 35 · 2019: 29 · 2018: 27 · 2017: 54 · 2016: 22
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma AG
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- fragile X syndrome, metabotropic glutamate receptor 5, mGluR5 antagonist, intellectual disability, autism spectrum disorder, behavioral symptoms, synaptic plasticity, drug safety and efficacy
- MeSH terms
- Adolescent, Adult, Age Factors, Behavior, Cognition, Demography, Double-Blind Method, Female, Fragile X Syndrome, Humans, Indoles, Male, Placebos, Least-Squares Analysis, Treatment Outcome, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.